115 related articles for article (PubMed ID: 35753554)
21. Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
Niibe Y; Nishimura T; Inoue T; Karasawa K; Shioyama Y; Jingu K; Shirato H
BMC Cancer; 2016 Aug; 16(1):659. PubMed ID: 27542716
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy".
Rieber J; Streblow J; Uhlmann L; Flentje M; Duma M; Ernst I; Blanck O; Wittig A; Boda-Heggemann J; Krempien R; Lohaus F; Klass ND; Eble MJ; Imhoff D; Kahl H; Petersen C; Gerum S; Henkenberens C; Adebahr S; Hass P; Schrade E; Wendt TG; Hildebrandt G; Andratschke N; Sterzing F; Guckenberger M
Lung Cancer; 2016 Jul; 97():51-8. PubMed ID: 27237028
[TBL] [Abstract][Full Text] [Related]
24. 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease.
Osti MF; Agolli L; Valeriani M; Reverberi C; Bracci S; Marinelli L; De Sanctis V; Cortesi E; Martelli M; De Dominicis C; Minniti G; Nicosia L
Lung Cancer; 2018 Aug; 122():165-170. PubMed ID: 30032826
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic Body Radiation Therapy in the Management of Oligometastatic and Oligoprogressive Bladder Cancer and Other Urothelial Malignancies.
Franzese C; Francolini G; Nicosia L; Alongi F; Livi L; Scorsetti M
Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):50-56. PubMed ID: 32723486
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
Fleckenstein J; Petroff A; Schäfers HJ; Wehler T; Schöpe J; Rübe C
BMC Cancer; 2016 Jun; 16():348. PubMed ID: 27255302
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
[TBL] [Abstract][Full Text] [Related]
28. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
Arcidiacono F; Aristei C; Marchionni A; Italiani M; Fulcheri CPL; Saldi S; Casale M; Ingrosso G; Anselmo P; Maranzano E
Br J Radiol; 2020 Nov; 93(1115):20200645. PubMed ID: 32822540
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
[TBL] [Abstract][Full Text] [Related]
30. Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
Franzese C; Badalamenti M; Teriaca A; De Virgilio A; Mercante G; Cavina R; Ferrari D; Santoro A; Spriano G; Scorsetti M
J Cancer Res Clin Oncol; 2021 May; 147(5):1307-1313. PubMed ID: 33471186
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiotherapy (SBRT) in the management of extracranial oligometastatic (OM) disease.
Bhattacharya IS; Woolf DK; Hughes RJ; Shah N; Harrison M; Ostler PJ; Hoskin PJ
Br J Radiol; 2015 Apr; 88(1048):20140712. PubMed ID: 25679321
[TBL] [Abstract][Full Text] [Related]
32. Stereotactic radiation therapy for oligometastatic esophagogastric adenocarcinoma: outcome and prognostic factors.
Franceschini D; Teriaca MA; Di Cristina L; Vernier V; Lo Faro L; Franzese C; Comito T; Clerici E; Bellu L; Dominici L; Spoto R; Massaro M; Navarria P; Scorsetti M
Br J Radiol; 2023 Mar; 96(1144):20220771. PubMed ID: 36809197
[TBL] [Abstract][Full Text] [Related]
33. Overall and chemotherapy-free survival following stereotactic body radiation therapy for abdominopelvic oligometastases.
Shahi J; Peng J; Donovan E; Vansantvoort J; Wong R; Tsakiridis T; Quan K; Parpia S; Swaminath A
J Med Imaging Radiat Oncol; 2020 Aug; 64(4):563-569. PubMed ID: 32497405
[TBL] [Abstract][Full Text] [Related]
34. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis.
Hong JC; Ayala-Peacock DN; Lee J; Blackstock AW; Okunieff P; Sung MW; Weichselbaum RR; Kao J; Urbanic JJ; Milano MT; Chmura SJ; Salama JK
PLoS One; 2018; 13(4):e0195149. PubMed ID: 29649281
[TBL] [Abstract][Full Text] [Related]
35. Long-term Follow-up and Patterns of Recurrence of Patients With Oligometastatic NSCLC Treated With Pulmonary SBRT.
Hörner-Rieber J; Bernhardt D; Blanck O; Duma M; Eich HT; Gerum S; Gkika E; Hass P; Henkenberens C; Herold HU; Hildebrandt G; Imhoff D; Kahl H; Janssen S; Jurianz K; Krempien R; Lautenschläger SF; Lohaus F; Mueller AC; Petersen C; Sackerer I; Scafa D; Schrade E; Uhlmann L; Wittig A; Guckenberger M
Clin Lung Cancer; 2019 Nov; 20(6):e667-e677. PubMed ID: 31327644
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
37. Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.
Kann BH; Verma V; Stahl JM; Ross R; Dosoretz AP; Shafman TD; Gross CP; Park HS; Yu JB; Decker RH
Radiother Oncol; 2019 May; 134():44-49. PubMed ID: 31005223
[TBL] [Abstract][Full Text] [Related]
38. Comparison of survival and prognostic factors in patients treated with stereotactic body radiotherapy for oligometastases or oligoprogression.
Pembroke CA; Fortin B; Kopek N
Radiother Oncol; 2018 Jun; 127(3):493-500. PubMed ID: 29735409
[TBL] [Abstract][Full Text] [Related]
39. Volumetric burden of metastatic lesions drives outcomes in patients with extracranial oligometastatic disease.
Cao Y; Chen H; Sahgal A; Erler D; Badellino S; Biswas T; Dagan R; Foote MC; Louie AV; Poon I; Ricardi U; Redmond KJ
Cancer Med; 2021 Nov; 10(22):8091-8099. PubMed ID: 34668651
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic body radiotherapy for pulmonary oligometastases: a monoinstitutional analysis of clinical outcomes and potential prognostic factors.
Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Nicosia L; Ricchetti F; Rigo M; Attinà G; Vitale C; Pastorello E; Ruggieri R; Alongi F
Strahlenther Onkol; 2022 Oct; 198(10):934-939. PubMed ID: 35499694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]